Share This Link

This mechanism of action describes the action of calcineurin inhibitors like cyclosporine, not prednisone. Prednisone does not directly inhibit calcineurin or interfere with the transcription of interleukin-2.

This statement is not accurate. Prednisone primarily acts by modulating immune cell function and reducing inflammation rather than interfering with nucleic acid synthesis.

This statement does not accurately describe the mechanism of action of prednisone. Prednisone acts through intracellular receptors rather than binding to antigens or surface receptors on immune cells.

It reduces inflammation, pain, fever, and allergic reactions by inhibiting the synthesis of prostaglandins and leukotrienes: This statement describes the pharmacologic effects of glucocorticoids, not mineralocorticoids like fludrocortisone. While fludrocortisone may have some mild anti-inflammatory effects, its primary role is related to electrolyte and fluid balance rather than inflammation modulation.

It regulates the secretion of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland, maintaining the feedback loop of cortisol production: This statement describes the role of cortisol, not fludrocortisone. Fludrocortisone primarily acts as a synthetic mineralocorticoid and does not directly regulate ACTH secretion or cortisol production.

It influences the carbohydrate, protein, and fat metabolism in various tissues, increasing blood glucose and suppressing immune response: This statement describes the pharmacologic effects of glucocorticoids like cortisol, not mineralocorticoids. Fludrocortisone has minimal impact on carbohydrate, protein, and fat metabolism and does not exert significant immunosuppressive effects.

Hyperglycemia, osteoporosis, glaucoma, and cataracts: These adverse effects are associated with systemic corticosteroid use, particularly when administered orally or by injection. When using inhaled corticosteroids like fluticasone, the systemic absorption is minimal, and the risk of these adverse effects is significantly lower compared to systemic administration.

Hypoglycemia, osteomalacia, myopia, and dry eyes: Hypoglycemia is not a commonly observed adverse effect of inhaled corticosteroids like fluticasone. Osteomalacia (softening of bones) is more commonly associated with long-term systemic corticosteroid use. Myopia (nearsightedness) and dry eyes are not typically seen as adverse effects of inhaled corticosteroids.

Oral ulcers, dysphagia, wheeze, and dyspnea: Oral ulcers, dysphagia (difficulty swallowing), wheeze, and dyspnea (difficulty breathing) are not commonly associated with inhaled corticosteroids and are not typical adverse effects of fluticasone.